Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Rectal Neoplasms 2Neoplasms 2Waldenstrom Macroglobulinemia 1Prostatic Neoplasms 1Paraproteinemias 1Lung Neoplasms 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Dexamethasone 12Bortezomib 9Lenalidomide 7Cyclophosphamide 5isatuximab 3fludarabine 3daratumumab 3Granulocyte Colony-Stimulating Factor 3pomalidomide 2filanesib 2dacetuzumab 2Tacrolimus 2Steroids 2Injections, Subcutaneous 2Filgrastim 2Clinical Protocols 2Calcium Dobesilate 2Alemtuzumab 2plerixafor 1ofatumumab 1nirogacestat 1fludarabine phosphate 1ficlatuzumab 1epratuzumab 1birtamimab 1Zoledronic Acid 1Whole-Body Irradiation 1Vorinostat 1Tissue Banks 1Thalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paraproteinemias × Rifaximin × Clear all
NCT03820817 2026-05-26

Rifaximin in Patients With Monoclonal Gammopathy

Emory University

Phase 1 Completed
50 enrolled
Lymphoid

Waldenstrom Macroglobulinemia, Paraproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡